Rexgenero Ltd, a clinical-stage regenerative medicine company developing advanced cell-based therapeutics with a focus on Critical Limb Ischemia (CLI), today announces it has secured, with its project consortium partners, £1.4 million in funding for a £1.8 million project from Innovate UK, the UK’s innovation agency, to lead an industrial research project of the commercial manufacture of its product REX-001.
The aim of the research project, entitled “Cost-driven process redesign, automation and scale-out for commercial manufacture of REX-001 therapy”, is to design a cost-effective manufacturing strategy for Rexgenero’s autologous cell-based therapy over a 21-month period. The grant is a consortium between the Cell and Gene Therapy (CGT) Catapult, TrakCel and Fisher Bioservices (part of Thermo Fisher Scientific).